S
Silvio E. Inzucchi
Researcher at Yale University
Publications - 511
Citations - 64889
Silvio E. Inzucchi is an academic researcher from Yale University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 92, co-authored 424 publications receiving 54101 citations. Previous affiliations of Silvio E. Inzucchi include University of Toronto & American Diabetes Association.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial
Jawad H. Butt,Jose C. Nicolau,Subodh Verma,Kieran F. Docherty,Mark C. Petrie,Silvio E. Inzucchi,Morten Schou,Mikhail Kosiborod,Anna Maria Langkilde,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Mikaela Sjöstrand,Scott D. Solomon,Olof Bengtsson,Pardeep S. Jhund,John J.V. McMurray,Lars Køber +17 more
TL;DR: In this paper, the efficacy and safety of dapagliflozin, compared with placebo, according to aetiology in patients with heart failure (HF) with reduced ejection fraction (HFrEF) enrolled in the DAPA-HF trial.
Journal ArticleDOI
Citizen Petition to the US Food and Drug Administration to Change Prescribing Guidelines: The Metformin Experience
TL;DR: Concerns over lactic acidosis have been examined and found to be largely unfounded unless kidney disease is advanced, and on the basis of the available data, metformin can be used safely and effectively for type 2 diabetes mellitus.
Journal ArticleDOI
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
David Fitchett,Silvio E. Inzucchi,Christoph Wanner,Michaela Mattheus,Jyothis T. George,Ola Vedin,Bernard Zinman,Odd Erik Johansen +7 more
TL;DR: In this post hoc exploratory analysis, hypoglycaemia was associated with an increased risk of HHF and MI, and empagliflozin improved CV outcomes, regardless of occurrence of hypoglycemia.
Journal ArticleDOI
Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.
Silvio E. Inzucchi,Kaan Tunceli,Y. Qiu,Swapnil Rajpathak,Kimberly G. Brodovicz,Samuel S. Engel,Panagiotis Mavros,Larry Radican,Philippe Brudi,Z. Li,Chun-Po Steve Fan,B. Hanna,J. Tang,Lawrence Blonde +13 more
TL;DR: Time to insulin initiation among patients with type 2 diabetes mellitus treated with sitagliptin versus sulphonylurea as add‐on to metformin is assessed.
Journal ArticleDOI
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function
Maria Alba,Bo Ahrén,Silvio E. Inzucchi,Y. Guan,M. Mallick,Lei Xu,Edward A. O'Neill,D. E. Williams-Herman,Keith D. Kaufman,Barry J. Goldstein +9 more
TL;DR: The effects of sitagliptin and pioglitazone, alone and in combination, on α‐ and β‐cell function were assessed in patients with type 2 diabetes.